Johnson & Johnson Medical Device Companies has announced that DePuy Synthes is launching the Attune Cementless Knee in a rotating platform option in select markets around the world.
This launch combines the technologies of the Attune Knee designed to provide stability while the knee is in motion with DePuy Synthes’ heritage in rotating platform knees and cementless technology.
The demand for cementless knee replacement is increasing, specifically for younger, more active patients for whom biological fixation and in-growth of the implant to bone may help meet the demands of their active lifestyle today and into the future. In the U.S., cementless total knee replacement procedures increased more than 25% from 2017 to 2018.
Ryan M. Nunley, associate professor and fellowship director at Washington University Orthopedics, Barnes Jewish Hospital, said: “The Attune Cementless Knee has the same great kinematic features of the cemented Attune Knee, but I feel the cementless technology is a better alternative for my younger and more active patients who have healthy, strong bone. These patients have the potential to remain active for many decades, and I think the evidence is growing that cementless knees have good long-term durability. I’ve implanted more than 400 Attune Cementless Knees in my practice with excellent early results.”
The Attune Cementless Knee is the latest addition to the comprehensive Attune Knee platform, which also includes a cemented primary knee system, a revision knee system and a tibial base with Attune S+ Technology designed to enhance intraoperative tibial fixation.
As with the cemented primary and revision systems, the Attune Cementless Knee features several patented technologies designed to improve knee function. These include the Attune Gradius Curve to provide stability through the range of motion and Glideright Articulation to more accurately replicate the normal relationship between the patella (knee cap) and femur.
In developing the Attune Cementless Knee, DePuy Synthes drew on its history of cementless and rotating platform technologies, including the LCS Cementless Knee - which has demonstrated an implant survivorship of 97.4% at a minimum 17-year follow-up.
In addition, all of the bone interfacing surfaces of the Attune Cementless Femoral Component are coated with Porocoat Porous Coating and the Attune Cementless Rotating Platform Tibial Base features four porous-coated pegs and central cone designed to enhance fixation of the implant to the bone.
Torbjorn Sköld, vice president, DePuy Synthes EMEA Joint Reconstruction, said: “With the Attune Cementless Knee, we have carried forward technologies and learnings from clinically proven devices like the LCS Knee and combined that with Attune Knee patented technologies to provide our customers a compelling solution to meeting emerging patient needs. Our strong hope and belief is that this implant system will help younger, more active patients get back to doing what they love if their surgeon feels they are the right candidate.”
The Attune Cementless Knee is initially being launched in the United States, select countries in Europe, Japan, Australia and New Zealand, with additional launches to follow. It is available in a cruciate retaining and posterior stabilised rotating platform construct as well as a hybrid construct.
